Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Sofinnova Investments-led syndicate forms CV play CinCor with $50M, Roche castoff

CinRx spinout launches to develop aldosterone synthase inhibitor for treatment-resistant hypertension, primary aldosteronism

Picking up one of Roche’s few remaining clinical cardiometabolism assets, Sofinnova Investments has joined Sofinnova Partners, 5AM Ventures and CinRx to launch CinCor with a $50 million series A and exclusive, worldwide rights to the pharma's aldosterone synthase inhibitor.

CinRx President and CEO Jon Isaacsohn told BioCentury the company acquired CIN-107

Read the full 516 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers